Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754495 | 0.90 | SCD (0.42) | ALDH1A1CYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL2662007 | 0.85 | PDE3B (0.37) | ALDH1A1LMNAMAPK1TSHRCYP1A2 | |
| SCHEMBL2657706 | 0.83 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPK1TSHRCYP1A2 | |
| SCHEMBL2658043 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPK1TSHRCYP1A2 | |
| SCHEMBL3748471 | 0.80 | NPSR1 (0.51) | ALDH1A1LMNAMAPK1TSHRNPSR1 | |
| SCHEMBL2660608 | 0.80 | NPSR1 (0.57) | ALDH1A1LMNAMAPK1TSHRPOLB | |
| SCHEMBL2661239 | 0.79 | CACNA1G (0.42) | ALDH1A1LMNAMAPK1TSHRCYP1A2 | |
| SCHEMBL28782750 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL3754458 | 0.78 | GCK (0.50) | ALDH1A1LMNAMAPK1TSHRNPSR1 | |
| SCHEMBL2660862 | 0.76 | HCAR1 (0.35) | ALDH1A1LMNAMAPK1TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155720-B1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2013-07-17 | — | — | EP | claimed |
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | claimed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | claimed |
| EP-2155720-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | Advinus Therapeutics Private Limited (IN) | 2010-02-24 | — | — | EP | claimed |
| WO-2008149382-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-12-11 | — | — | WO | claimed |
| EP-2155720-B1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2013-07-17 | — | — | EP | disclosed |
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | disclosed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | ALDH1A1 1904/4885LMNA 3790/4885MAPK1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.